dc.contributor.author |
Málaga Rodríguez, Germán Javier |
|
dc.contributor.author |
Ruiz, Eloy F. |
|
dc.date.accessioned |
2019-12-06T20:57:42Z |
|
dc.date.available |
2019-12-06T20:57:42Z |
|
dc.date.issued |
2019 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/7365 |
|
dc.description.abstract |
Evidence that sodium-glucose co-transporter-2 inhibitors (SGLT2i) can reduce cardiovascular risk—with trials showing reductions in cardiovascular death, myocardial infarction, and stroke—would suggest they have much to offer in the care of patients with type 2 diabetes at high risk of cardiovascular events. But should they be used in patients at low risk?... |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Elsevier |
|
dc.relation.ispartofseries |
Lancet |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Diabetes Mellitus, Type 2 |
en_US |
dc.subject |
Dipeptidyl-Peptidase IV Inhibitors |
en_US |
dc.subject |
Sodium-Glucose Transporter 2 Inhibitors |
en_US |
dc.subject |
acetylsalicylic acid |
en_US |
dc.subject |
acute heart failure |
en_US |
dc.subject |
antidiabetic agent |
en_US |
dc.subject |
cardiovascular disease |
en_US |
dc.subject |
cause of death |
en_US |
dc.subject |
Diabetes Mellitus, Type 2 |
en_US |
dc.subject |
dipeptidyl peptidase IV inhibitor |
en_US |
dc.subject |
Dipeptidyl-Peptidase IV Inhibitors |
en_US |
dc.subject |
disease course |
en_US |
dc.subject |
geriatric disorder |
en_US |
dc.subject |
heart failure with preserved ejection fraction |
en_US |
dc.subject |
heart failure with reduced ejection fraction |
en_US |
dc.subject |
heart infarction |
en_US |
dc.subject |
human |
en_US |
dc.subject |
Humans |
en_US |
dc.subject |
hydroxymethylglutaryl coenzyme A reductase inhibitor |
en_US |
dc.subject |
Hypoglycemic Agents |
en_US |
dc.subject |
intervention study |
en_US |
dc.subject |
kidney function |
en_US |
dc.subject |
Letter |
en_US |
dc.subject |
multiple chronic conditions |
en_US |
dc.subject |
non insulin dependent diabetes mellitus |
en_US |
dc.subject |
patient care |
en_US |
dc.subject |
personalized medicine |
en_US |
dc.subject |
priority journal |
en_US |
dc.subject |
risk factor |
en_US |
dc.subject |
risk reduction |
en_US |
dc.subject |
secondary prevention |
en_US |
dc.subject |
Secondary Prevention |
en_US |
dc.subject |
sodium glucose cotransporter 2 inhibitor |
en_US |
dc.subject |
Sodium-Glucose Transporter 2 Inhibitors |
en_US |
dc.title |
SGLT-2 inhibitors for people with type 2 diabetes. |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1016/S0140-6736(19)30720-2 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.02.00 |
|
dc.relation.issn |
1474-547X |
|